Primary aldosteronism and aldosterone-associated hypertension

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Nephrology

Background:

• Primary aldosteronism (PA) has evolved from a rare condition to a common cause of hypertension, particularly in specific patient groups.
• PA and aldosterone-related hypertension are associated with increased cardiovascular and renal risks compared to essential hypertension.
• Aldosterone's effects extend to metabolic syndrome and diabetes, highlighting its systemic impact.

Purpose of the Study:

• To review the current understanding and diagnostic approaches to primary aldosteronism.
• To discuss the utility and limitations of screening tests like the aldosterone-to-renin ratio (ARR).
• To outline confirmatory tests and imaging modalities for PA diagnosis and management.

Main Methods:

• Review of current literature on primary aldosteronism and aldosterone-related hypertension.
• Discussion of screening criteria, including ARR, and its associated challenges.
• Evaluation of confirmatory diagnostic tests such as suppression tests, aldosterone excretion, and adrenal venous sampling.
• Consideration of imaging techniques like CT and scintigraphy.
• Assessment of spironolactone's role in managing resistant and aldosterone-related hypertension.

Main Results:

• The aldosterone-to-renin ratio (ARR) facilitates widespread screening but requires careful interpretation due to variable cut-off values and specificity issues.
• Confirmatory tests including fludrocortisone suppression, saline infusion, and 24-hour aldosterone excretion are necessary for positive ARR screens.
• Adrenal venous sampling is the gold standard for identifying aldosterone-producing adenomas, with CT and scintigraphy as alternatives.
• Spironolactone shows promise as a key antihypertensive agent for resistant and aldosterone-related hypertension.

Conclusions:

• Primary aldosteronism is a significant contributor to hypertension-related morbidity, necessitating appropriate screening and diagnosis.
• While ARR is a valuable screening tool, its limitations require confirmation with more specific tests.
• Accurate diagnosis through suppression tests and imaging guides targeted treatment, including the use of mineralocorticoid receptor antagonists like spironolactone.